Jazz Pharmaceuticals plc’s filing revealed that its Chairman & CEO COZADD BRUCE C unloaded Company’s shares for reported $55000.0 on Jun 03 ’25. In the deal valued at $110.00 per share,500 shares were sold. As a result of this transaction, COZADD BRUCE C now holds 437,973 shares worth roughly $48.02 million.
Then, COZADD BRUCE C sold 500 shares, generating $53,950 in total proceeds. Upon selling the shares at $107.90, the Chairman & CEO now owns 438,473 shares.
Before that, COZADD BRUCE C bought 1,000 shares. Jazz Pharmaceuticals plc shares valued at $108,950 were divested by the Officer at a price of $108.95 per share.
UBS upgraded its Jazz Pharmaceuticals plc [JAZZ] rating to a Buy from a a Neutral in a research note published on March 07, 2025; the price target was increased to $179 from $145. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who decreased its forecast for the stock in late February from “an Overweight” to “a Neutral”. Wells Fargo also remained covering JAZZ and has increased its forecast on February 13, 2025 with a “an Overweight” recommendation from previously “an Equal weight” rating. Morgan Stanley revised its rating on December 12, 2024. It rated JAZZ as “an Overweight” which previously was an “an Equal-weight”.
Price Performance Review of JAZZ
On Monday, Jazz Pharmaceuticals plc [NASDAQ:JAZZ] saw its stock jump 1.05% to $109.64. Over the last five days, the stock has lost -1.99%. Jazz Pharmaceuticals plc shares have fallen nearly -10.97% since the year began. Nevertheless, the stocks have fallen -1.24% over the past one year. While a 52-week high of $148.06 was reached on 02/26/25, a 52-week low of $95.49 was recorded on 04/09/25.
Levels Of Support And Resistance For JAZZ Stock
The 24-hour chart illustrates a support level at 108.29, which if violated will result in even more drops to 106.93. On the upside, there is a resistance level at 110.53. A further resistance level may holdings at 111.41.
The most recent change occurred on June 05, 2024 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $169 price target.
